Opinion|Videos|May 2, 2025
Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
Panelists discuss how, Copper-64 (^64Cu)–labeled PSMA-targeted PET imaging is emerging as a promising modality in prostate cancer diagnosis. The phase 2 SOLAR study (NCT05653856) demonstrated that ^64Cu-PSMA I&T PET/CT effectively detects metastatic prostate cancer, meeting primary end points related to correct localization rates. Compared with gallium-68 (^68Ga) and fluorine-18 (^18F), ^64Cu offers a half-life of approximately 12.7 hours, facilitating centralized production and distribution, which may improve accessibility
Advertisement
Video content above is prompted by the following:
- Discuss the emerging role of CU-PSMA-targeted PET imaging in prostate cancer.
- SOLAR phase 2 study – Cu-64-PSMA I&T (NCT05653856)
- 61Cu-PSMA–targeted PET for prostate cancer (Bernabeu et al. J Nucl Med. 2024)
- How do copper isotopes compare with others (gallium and fluorine) in terms of half-life, production logistics, image quality, etc?
- What potential advantages may copper-based isotopes offer over gallium or fluorine isotopes?
- Where do you see Cu-PSMA–targeted PET fitting in the current treatment landscape, and how might it influence future treatment approaches in prostate cancer?
Advertisement
Related to this article
Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma.
The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
3
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
4
Using Intrathecal Dendritic Cells for Leptomeningeal Disease From Breast Cancer
5